Gynecologic Cancer News

Cytoreductive surgery before chemotherapy led to significant and clinically meaningful OS and PFS benefits for women with recurrent ovarian cancer, according to a phase 3 study published in The New England Journal of Medicine.

Mirvetuximab soravtansine induced confirmed objective response in about one-third of women with folate receptor alpha-high platinum-resistant ovarian cancer who previously received bevacizumab, according to the agent’s manufacturer.

The FDA approved the imaging drug pafolacianine to help surgeons identify ovarian cancer lesions.

Emese Zsiros, MD, PhD, has been promoted to lead the department of gynecologic oncology at Roswell Park Comprehensive Cancer Center.

Transgender men and nonbinary individuals derived benefit from a pilot program designed to offer cervical cancer screening specific to their biological needs and personal preferences, according to study results.

Half of patients with relapsed or refractory solid tumors achieved objective response to an infusion of IMA203, according to study results presented at Society for the Immunotherapy of Cancer Annual Meeting.

More than 80% of therapies tested in phase 3 oncology trials did not demonstrate clinically meaningful benefit in extending survival, according to results of a study published in JNCCN — Journal of the National Comprehensive Cancer Network.

The offspring of mothers who received 17-hydroxyprogesterone caproate during pregnancy may face nearly double the risk for cancer compared with those who were not exposed, according to a recent study.

Unemployment appeared associated with a lower likelihood of having health insurance and of being up to date on cancer screening tests, according to results of a study published in Cancer.

An HPV vaccination intervention that was implemented in schools modestly improved psychosocial vaccine-related outcomes like decision-making in adolescents, according to findings published in JAMA Network Open.